Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis

Drugs under Experimental and Clinical Research

Volumn 30, Issue 2, 2004, Pages 47-54

  Szabo, S ^a,c   Etzel, D ^b   Ehlers, R ^b   Walter, T ^b   Kazmaier, S ^b   Helber, U ^b   Beyer, M E ^b   Hoffmeister, H M ^a  

^a Pathologisches Institut   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRIN; HEPARIN; PLASMIN; RETEPLASE; THROMBIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG SPECIFICITY; ELECTROCARDIOGRAM; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HEMOSTASIS; HUMAN; IN VIVO STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION;

AGED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3142673323     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 340, 115, 1999.
2. Watanabe T., Haraoka S., Shimokama T. Inflammatory and immunological nature of atherosclerosis. Int. J. Cardiol., 54 (Suppl.), S51, 1996.
3. Balter M. AIDS now world's fourth biggest killer. Science, 284, 1101, 1999.
4. Fitzgerald D.J., Catella F., Roy L., et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation, 77, 142, 1988.
5. Kerins D.M., Roy L., Fitzgerald D.J. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation, 80, 1718, 1989.
6. Hoffmeister H.M., Szabo S., Kastner C., et al. Thrombolytic therapy in acute myocardial infarction: Comparison of procoagulant effects of streptokinase and alteplase regimen with focus on the kallikrein system and plasmin. Circulation, 98, 2527, 1998.
7. Szabo S., Letsch R., Ehlers R., et al. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction. Comparison of single bolus tenecteplase and front-loaded alteplase. Thromb. Res., 106, 113, 2002.
8. Bazzoni G., Dejana E., Del Maschio A. Platelet-neutrophil interactions: possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica, 76, 491, 1991.
9. Palabrica T., Lobb R., Furie B.C., et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature, 359, 848, 1992.
10. Ruf A., Schlenk R.F., Maras A., et al. Contact-induced neutrophil activation by platelets in human cell suspensions and whole blood. Blood, 80, 1238, 1992.
11. 2-integrin to enhance phagocytosis. J. Immunol., 153, 3199, 1994.
12. McEver R.P. Selectins. Curr. Opin. Immunol., 6, 75, 1994.
13. Spangenberg P., Redlich H., Bergmann I., et al. The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb. Haemost., 70, 514, 1993.
14. Ruf A., Patscheke H. Platelet-induced neutrophil activation: Platelet-expressed fibrinogen induced the oxidative burst in neutrophils by an interaction with CD11c/CD18. Br. J. Haematol., 90, 791, 1995.
15. Boukerche H., Ruchaud-Sparagano M.H., Rouen C., et al. A monoclonal antibody directed against a granule membrane glycoprotein (GMP-140/PADGEM, P-selectin, CD 62P) inhibits ristocetin-induced platelet aggregation. Br. J. Haematol., 92, 442, 1996.
16. Ewald G.A., Eisenberg P.R. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation, 91, 28, 1995.
17. Agostoni A., Gardinali M., Frangi D., et al. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. Circulation, 90, 2666, 1994.
18. Kleniewsky J., Blankenship D.T., Cardin A.D., et al. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J. Lab. Clin. Med., 120, 129, 1992.
19. Topol E.J., Califf R.M., Van de Werf F., et al. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy of combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet, 357, 1905, 2001.
20. Moliterno D.J., Califf R.M., Aguirre F.V., et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (The EPIC Trial). Am. J. Cardiol., 75, 559, 1995.
21. Mascelli M.A., Worley S. Veriabo N.J., et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation, 96, 3860, 1997.
22. Hoffmeister H.M., Kastner C., Szabo S., et al. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction. Am. J. Cardiol., 86, 263, 2000.
23. Cugno M., Cicardi M., Bottasso B., et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood, 89, 3213, 1997.
24. Hoffmeister H.M., Ruf M., Wendel H.P., et al. Streptokinase-induced activation of the kallikrein-kinin system and of the contact phase in patients with acute myocardial infarction. J. Cardiovasc. Pharmacol., 31, 764, 1998.
25. Moser M., Nordt T., Peter K., et al. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation, 100, 1858, 1999.
26. Martinez-Sales V., Vila V., Reganon E., et al. Elevated thrombotic activity after myocardial infarction: A 2-year follow-up study. Haemostasis, 28, 301, 1998.
27. Coppola R., Cristilli R., Cugno M., et al. Measurement of activated factor XII in health and disease. Blood Coagul. Fibrinolysis, 7, 530, 1996.
28. Kohler H.P., Carter A.M., Stickland M.H., et al. Levels of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb. Haemost., 79, 1, 1998.
29. Szabo S., Etzel D., Walter T., et al. Benefical effects of r-PA in combination with abciximab: Platelet- / leukocyte-interactions and coagulation system. Eur. Heart J. (Abstract Suppl.), 24, 198, 2003.
30. Lincoff A.M., Califf R.M., Van de Werf F., et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA, 288, 2130, 2002.